Acral Lentiginous Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acral lentiginous melanoma markets are expected to exhibit a CAGR of 3.3% during 2024-2034.
The acral lentiginous melanoma market has been comprehensively analyzed in IMARC's new report titled "Acral Lentiginous Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acral lentiginous melanoma is a malignant skin cancer that develops from melanocytes, the cells responsible for producing the pigment melanin. It commonly occurs on hairless skin with little to no sun exposure, which includes the palms of the hands, the soles of the feet, and under the nails. The symptom of this ailment often begins as a dark spot, lesion, or patch that may be itchy, tender, or painful. The color of the lesion can vary, ranging from brown to black or even shades of red, blue, or white. If melanoma develops under a nail, it might cause changes in the shape, texture, or thickness of the nail. The diagnosis of this illness typically involves a combination of clinical examination, medical history, and physical tests. The healthcare provider may perform a dermoscopy that uses a special magnifying instrument to evaluate the skin's structures and patterns. This investigation also helps to assess pigmented lesions for signs of malignancy. Various diagnostic procedures, such as X-rays, ultrasounds, CT scans, etc., are utilized to determine the extent of the disease in patients.
The increasing cases of genetic mutations, which can lead to continuous activation of cell signaling pathways, thereby promoting uncontrolled tissue proliferation, are primarily driving the acral lentiginous melanoma market. In addition to this, the expanding geriatric population who are susceptible to a weakened immune system, making it more challenging for the body to control and eliminate cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapy, owing to its several benefits, such as local tumor eradication, minimal invasiveness, reduced risk of recurrence, etc., is further bolstering the market growth. Apart from this, the inflating application of immunotherapy, since it works by leveraging the body's own immune system to locate and disrupt cancerous cells, thereby boosting long-term survival, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of Mohs micrographic surgery, which involves the precise removal of layers of tissue and real-time examination under a microscope to ensure that all abnormal cells are removed while sparing healthy tissue, is expected to drive the acral lentiginous melanoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acral lentiginous melanoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acral lentiginous melanoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acral lentiginous melanoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acral lentiginous melanoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acral lentiginous melanoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acral lentiginous melanoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acral lentiginous melanoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acral lentiginous melanoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acral lentiginous melanoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acral lentiginous melanoma across the seven major markets?
What is the size of the acral lentiginous melanoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acral lentiginous melanoma?
What will be the growth rate of patients across the seven major markets?
Acral Lentiginous Melanoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acral lentiginous melanoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acral lentiginous melanoma market?
What are the key regulatory events related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by status related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by phase related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by route of administration related to the acral lentiginous melanoma market?
The acral lentiginous melanoma market has been comprehensively analyzed in IMARC's new report titled "Acral Lentiginous Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acral lentiginous melanoma is a malignant skin cancer that develops from melanocytes, the cells responsible for producing the pigment melanin. It commonly occurs on hairless skin with little to no sun exposure, which includes the palms of the hands, the soles of the feet, and under the nails. The symptom of this ailment often begins as a dark spot, lesion, or patch that may be itchy, tender, or painful. The color of the lesion can vary, ranging from brown to black or even shades of red, blue, or white. If melanoma develops under a nail, it might cause changes in the shape, texture, or thickness of the nail. The diagnosis of this illness typically involves a combination of clinical examination, medical history, and physical tests. The healthcare provider may perform a dermoscopy that uses a special magnifying instrument to evaluate the skin's structures and patterns. This investigation also helps to assess pigmented lesions for signs of malignancy. Various diagnostic procedures, such as X-rays, ultrasounds, CT scans, etc., are utilized to determine the extent of the disease in patients.
The increasing cases of genetic mutations, which can lead to continuous activation of cell signaling pathways, thereby promoting uncontrolled tissue proliferation, are primarily driving the acral lentiginous melanoma market. In addition to this, the expanding geriatric population who are susceptible to a weakened immune system, making it more challenging for the body to control and eliminate cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapy, owing to its several benefits, such as local tumor eradication, minimal invasiveness, reduced risk of recurrence, etc., is further bolstering the market growth. Apart from this, the inflating application of immunotherapy, since it works by leveraging the body's own immune system to locate and disrupt cancerous cells, thereby boosting long-term survival, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of Mohs micrographic surgery, which involves the precise removal of layers of tissue and real-time examination under a microscope to ensure that all abnormal cells are removed while sparing healthy tissue, is expected to drive the acral lentiginous melanoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acral lentiginous melanoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acral lentiginous melanoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acral lentiginous melanoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acral lentiginous melanoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acral lentiginous melanoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acral lentiginous melanoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acral lentiginous melanoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acral lentiginous melanoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acral lentiginous melanoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acral lentiginous melanoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acral lentiginous melanoma across the seven major markets?
What is the size of the acral lentiginous melanoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acral lentiginous melanoma?
What will be the growth rate of patients across the seven major markets?
Acral Lentiginous Melanoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acral lentiginous melanoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acral lentiginous melanoma market?
What are the key regulatory events related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by status related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by phase related to the acral lentiginous melanoma market?
What is the structure of clinical trial landscape by route of administration related to the acral lentiginous melanoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACRAL LENTIGINOUS MELANOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACRAL LENTIGINOUS MELANOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACRAL LENTIGINOUS MELANOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACRAL LENTIGINOUS MELANOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACRAL LENTIGINOUS MELANOMA - UNMET NEEDS
10 ACRAL LENTIGINOUS MELANOMA - KEY ENDPOINTS OF TREATMENT
11 ACRAL LENTIGINOUS MELANOMA - MARKETED PRODUCTS
11.1 List of Acral Lentiginous Melanoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACRAL LENTIGINOUS MELANOMA - PIPELINE DRUGS
12.1 List of Acral Lentiginous Melanoma Pipeline Drugs Across the Top 7 Markets
12.1.1 MDNA11 – Medicenna Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACRAL LENTIGINOUS MELANOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACRAL LENTIGINOUS MELANOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACRAL LENTIGINOUS MELANOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acral Lentiginous Melanoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acral Lentiginous Melanoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acral Lentiginous Melanoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acral Lentiginous Melanoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acral Lentiginous Melanoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acral Lentiginous Melanoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acral Lentiginous Melanoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acral Lentiginous Melanoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
16 ACRAL LENTIGINOUS MELANOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACRAL LENTIGINOUS MELANOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACRAL LENTIGINOUS MELANOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACRAL LENTIGINOUS MELANOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACRAL LENTIGINOUS MELANOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACRAL LENTIGINOUS MELANOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACRAL LENTIGINOUS MELANOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACRAL LENTIGINOUS MELANOMA - UNMET NEEDS
10 ACRAL LENTIGINOUS MELANOMA - KEY ENDPOINTS OF TREATMENT
11 ACRAL LENTIGINOUS MELANOMA - MARKETED PRODUCTS
11.1 List of Acral Lentiginous Melanoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACRAL LENTIGINOUS MELANOMA - PIPELINE DRUGS
12.1 List of Acral Lentiginous Melanoma Pipeline Drugs Across the Top 7 Markets
12.1.1 MDNA11 – Medicenna Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACRAL LENTIGINOUS MELANOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACRAL LENTIGINOUS MELANOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACRAL LENTIGINOUS MELANOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acral Lentiginous Melanoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acral Lentiginous Melanoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acral Lentiginous Melanoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acral Lentiginous Melanoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acral Lentiginous Melanoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acral Lentiginous Melanoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acral Lentiginous Melanoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acral Lentiginous Melanoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acral Lentiginous Melanoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acral Lentiginous Melanoma - Access and Reimbursement Overview
16 ACRAL LENTIGINOUS MELANOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACRAL LENTIGINOUS MELANOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACRAL LENTIGINOUS MELANOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
